肿瘤标志物案例,教你分析检验报告单

2018-07-06 王启杰 检验医学网

64岁女性,吸烟者( 90包/年),有高血压和COPD史,出现持续咳嗽和咯血。


64岁女性,吸烟者( 90包/年),有高血压和COPD史,出现持续咳嗽和咯血。



报告:SCC、CEA和CYFR21-1轻度升高,可能为肾功能损害引起。ProGRP水平应排除小细胞肺肿瘤或神经内分泌肿瘤。

诊断胸腔内小细胞癌。

评论:急性或慢性肾衰竭是引起TM假阳性的主要原因。CEA、SCC或CYFR21-1轻微升高可能与肾衰竭有关。肾衰竭患者常有ProGRP升高,但其水平很少超过300-350pg/ml。较高水平则明确提示为肿瘤, SCUC或神经内分泌肿瘤。在两者间鉴别诊断是很困难的,由于肾衰竭,其他TMs必须当作阴性。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-07 kafei

    学习下谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1841262, encodeId=cf8c18412629f, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Wed Aug 29 19:11:00 CST 2018, time=2018-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967508, encodeId=fdba196e50847, content=<a href='/topic/show?id=453a625828f' target=_blank style='color:#2F92EE;'>#检验报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62582, encryptionId=453a625828f, topicName=检验报告单)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat Apr 27 11:11:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668604, encodeId=0aaa166860420, content=<a href='/topic/show?id=d6af560460e' target=_blank style='color:#2F92EE;'>#报告单#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56046, encryptionId=d6af560460e, topicName=报告单)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435426361898, createdName=zlawrance, createdTime=Thu Aug 02 20:11:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956998, encodeId=ef44195699846, content=<a href='/topic/show?id=00fe62580f6' target=_blank style='color:#2F92EE;'>#检验报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62580, encryptionId=00fe62580f6, topicName=检验报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Tue Jun 18 17:11:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329951, encodeId=b62232995161, content=学习下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Jul 07 09:51:22 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=329802, encodeId=80b5329802e2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Jul 06 20:32:57 CST 2018, time=2018-07-06, status=1, ipAttribution=)]
    2018-07-06 医者仁心5538

    学习了

    0

相关资讯

上海癌症全新数据公布,我们来说说肿瘤标志物检测的事儿

近日,上海发布公布了本市癌症的相关数据:上海男性最常见癌症是肺癌、大肠癌、胃癌、肝癌和前列腺癌;上海女性最常见癌症为甲状腺癌、乳腺癌、肺癌、大肠癌和胃癌。癌症预防很重要!所以,现在很多市民的年度体检套餐里都有“肿瘤标志物检测”项目啦!周浦医院肿瘤血液科的副主任医师周莉介绍说,肿瘤标志物的检测现在已经很普遍,因为这项检测对医生及时为肿瘤病人选择个体化治疗方案有很大的帮助。肿瘤标志物升高≠癌症血清肿瘤

除了筛查,肺癌肿瘤标志物还有什么用处?

肺癌已经成为我国每年患病人数和死亡人数最多的肿瘤,关于肺癌的早期筛查和诊断起来越受到人们的关注。肿瘤标志物是1978年Herberman在美国国立癌症研究院召开的人类免疫及肿瘤免疫诊断会上提出的,1979年在英国第七届肿瘤发生生物学和医学会议上作为专用术语被大家公认。三十余年来,肿瘤标志物的研究逐渐形成了一门独立的学科分支。

详解16种肿瘤标志物,看完不再困惑

肿瘤标志物在1978年就被发现了,它是指在血液、体液及组织中可检测到的与肿瘤相关的物质,达到一定水平时,可反映某些肿瘤的存在。

手把手教你分析检验报告单,肿瘤标志物案例

53岁女性,曾经吸烟,无疾病史,常规胸部X线检查发现肺部阴影。

这些肿瘤标志物的意义你知道吗?

肿瘤标志物(Tumor markers,TM)是恶性肿瘤发生和增殖过程中,肿瘤细胞基因表达而合成分泌的,或由机体对肿瘤反应而异常产生或升高的,反映肿瘤存在和生长的一类物质,存在于病人的血液、体液、细胞或组织中,可用生物化学,免疫学及分子生物学等方法测定,对肿瘤的辅助诊断、鉴别诊断、观察疗效、监测复发和预后评价具有临床价值。

父亲节带父体检,别被这些肿瘤指标吓到了

作为“百病之王”的癌症,这几年发病率逐渐攀升,让大家“谈癌色变”,加上“亚健康”、“癌症早期筛查”等概念的广泛传播,定期体检已经成为健康生活,预防癌症的“政治正确”。数据显示,我国男性肿瘤的发病率在50岁以后随年龄增加而大幅上升,男性的发病率与死亡率均高于女性。父亲节将至,商家纷纷借势推出“父亲节肿瘤体检套餐”,噱头感十足。可孝顺的子女们是否知道,这些套餐项目并不一定能准确查出癌症!肿瘤标志物